PRC
RCKT icon

Pearl River Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Pearl River Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,712
Closed -$208K – 586
2024
Q1 		$208K Buy
+7,712
New +$219K 0.03% 436

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pearl River Capital's RCKT Position: Q2 2024 in Review

Pearl River Capital sold out of Rocket Pharmaceuticals (RCKT) in Q2 2024, closing a stake of 7,712 shares — an estimated $208K sold.

Pearl River Capital first reported a position in RCKT in Q1 2024 and held it in 1 quarter. The position peaked at $208K in Q1 2024. 178 funds tracked by Wall St. Rank hold RCKT as of Q2 2024.

  • Pearl River Capital reported no remaining Rocket Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Pearl River Capital sold 7,712 Rocket Pharmaceuticals shares in Q2 2024, an estimated $208K.
  • Pearl River Capital first reported a position in Rocket Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Pearl River Capital's Rocket Pharmaceuticals position peaked at $208K in Q1 2024.
  • 178 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2024.

Based on Pearl River Capital's 13F filing for Q2 2024, filed 13 Aug 2024.